Sara Raponi

Sara Raponi

Auto-generated profile, based on publicly available information

Sara Raponi

Hematology, Department of Translational and Precision Medicine Sapienza University Rome Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2014 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
Massimo BrecciaMassimo Breccia
Massimo Breccia
MPMaria Stefania De Propris
Maria Stefania De Propris
CSCaterina Stefanizzi
Caterina Stefanizzi
SRSara Raponi
Sara Raponi
MMMatteo Molica
Matteo Molica
RFRobin Foà
Robin Foà

16 February 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
SRSara Raponi
Sara Raponi
CICaterina Ilari
Caterina Ilari
ISIrene Della Starza
Irene Della Starza
LCLuca Vincenzo Cappelli
Luca Vincenzo Cappelli
LCLuciana Cafforio
Luciana Cafforio
RFRobin Foà
Robin Foà

18 October 2018 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
AGAnna Guarini
Anna Guarini
NPNadia Peragine
Nadia Peragine
MMMonica Messina
Monica Messina
MMMarilisa Marinelli
Marilisa Marinelli
CICaterina Ilari
Caterina Ilari
RFRobin Foà
Robin Foà

12 October 2015 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
MCMarzia Cavalli
Marzia Cavalli
CICaterina Ilari
Caterina Ilari
IGIlaria Del Giudice
Ilaria Del Giudice
MMMarilisa Marinelli
Marilisa Marinelli
ISIrene Della Starza
Irene Della Starza
RFRobin Foà
Robin Foà

15 February 2023 in British Journal of Haematology
Verified
Journal Article
Closed access
IGIlaria Del Giudice
Ilaria Del Giudice
LCLuca Vincenzo Cappelli
Luca Vincenzo Cappelli
JDJulio Delgado
Julio Delgado
CNCarsten Utoft Niemann
Carsten Utoft Niemann
MAMichael Asger Andersen
Michael Asger Andersen
RFRobin Foà
Robin Foà

26 June 2023 in British Journal of Haematology
Verified
Journal Article
Open access
GRGian Matteo Rigolin
Gian Matteo Rigolin
ATAlice Traversa
Alice Traversa
VCViviana Caputo
Viviana Caputo
IGIlaria Del Giudice
Ilaria Del Giudice
ABAntonella Bardi
Antonella Bardi
ACAntonio Cuneo
Antonio Cuneo
We explored the relevance of genomic microarrays (GM) in the refinement of prognosis in newly diagnosed low-risk chronic lymphocytic leukaemia (CLL) patients as defined by isolated del(13q) or no lesions by a standard 4 probe fluorescence in situ hybridization (FISH) analysis. Compared to FISH, additional lesions were detected by GM in 27 of the 119 patients (22.7%). The concordance rate between FISH and GM was 87.4%. Discordant results between cytogenetic banding analysis (CBA) and GM were observed in 45/119 cases (37.8%) and were mainly due to the intrinsic characteristics of each technique. The presence of additional lesions by GM was associated with age > 65 years (p = 0.047), advanced Binet stage (p = 0.001), CLL-IPI score (p < 0.001), a complex karyotype (p = 0.004) and a worse time-to-first treatment in multivariate analysis (p = 0.009). Additional lesions by GM were also significantly associated with a worse time-to-first treatment in the subset of patients with wild-type TP53 and mutated IGHV (p = 0.025). In CLL patients with low-risk features, the presence of additional lesions identified by GM helps to identify a subset of patients with a worse outcome that could be proposed for a risk-adapted follow-up and for early treatment including targeted agents within clinical trials.